For Market Access
For payer strategy, contracting and pricing, and trade and channel. We measure what preferred and non-preferred status deliver in uptake and persistence, for your product and your competitors, so the discount on the table can be set against the volume it returns. We follow the coverage win downstream to the specialty pharmacy, the site, and the writer where pull-through breaks. And we read the mix, channel, and 340B shifts in claims a quarter before they reach finance.
One example, from our published research
43%
of 72,245 patients did what the formulary intended.
A third were never disrupted. About 10,200 stopped GLP-1 therapy while still in care with an obesity diagnosis. Forced switchers persisted 14.1 points below undisrupted controls at six months.
The CVS Caremark Forced SwitchIn practice
Formulary policy doesn’t always match what the payer enforces, and the link from control to volume is genuinely difficult to see. So the position’s return is argued from analog and the payer’s own framing, and the walkaway price rests on it.
Each line is accurate. An account can sit at the top on patient-facing metrics while 340B routing, Medicaid share, and competitor share compound underneath it. The pressure is only visible across all three at once.
After a coverage win, the loss is often in the office or the pharmacy handoff: a rejection nobody worked back. Attributed to the payer, it points the fix at a negotiation that won’t help.
Our answer
The answer is never just the headline. Every finding comes with the mechanism behind it, how it has moved over recent quarters, the confounders we tested and ruled out, and an explicit account of what the data cannot tell you.
01
Uptake, persistence, and time-to-fill under preferred vs non-preferred, for your product and competitors, across payers. Including the case where the position doesn’t pay for itself.
02
Negotiated reimbursement rates, GPO affiliation, and open and closed claims, against the volume you already track. The sites earning the best margin on your product are visible — not just the ones moving the most volume.
03
Pull-through by specialty pharmacy, site, and writer. Who resubmits after a rejection and who doesn’t.
04
Channel mix, 340B, Medicaid concentration, and site dynamics as they move in claims, a quarter before reconciliation.
Example analyses
A sample. If it’s in claims, it’s in scope.
The output is not a metric. It is a working understanding of your market — the kind you would otherwise assemble by hand, months after it had already shifted again — and a short, ordered list of where your attention should go first.
What we do
Most analytics, human or AI, spend their attention on the question you bring. One question, one answer. The finding that changes a quarter usually sits between hundreds of cross-tabs no one thought to triangulate.
Bring a question.
Your consultant in a pocket. One brand or access question. The defensible answer in five business days, with the mechanism and the accounts behind it.
Watches what you aren't.
Every brand team tracks a set of numbers. Sonar goes after what sits between them.
What you receive
Researcher or Sonar, every project ends with the same five things.
An online report. The full finding and every cut behind it.
An assistant on the report that answers follow-up questions on your own time.
The entities behind the finding. HCPs, accounts, specialty pharmacies, infusion centers, payers — as applicable to the finding — each with a behavioral profile, exportable to your CRM. The outsized drivers, not a spreadsheet no one reads.
A live readout with your account strategy partner — the Flyway analyst who conducted the run and audited the results — and the same partner for follow-ups.
A deck you can forward: the finding, the mechanism, and any accounts behind it, ready for a leadership meeting.
Tell us the change. We'll tell you how we'd go about it, and whether the data can support it.